Literature DB >> 29605873

Clinical characteristics and outcomes of diffuse large B-cell lymphoma in adolescents and young adults.

Yasuhiro Suzuki1,2, Takahiro Yano3, Youko Suehiro4, Hiromi Iwasaki5, Michihiro Hidaka6, Maki Otsuka7, Kazutaka Sunami8, Nobumasa Inoue9, Morio Sawamura10, Takuo Ito11, Hiroatsu Iida12, Hirokazu Nagai12,13.   

Abstract

Clinical information regarding non-Hodgkin lymphoma (NHL) in adolescents and young adults (AYA) is lacking. We retrospectively analyzed 1426 consecutively registered patients with newly diagnosed NHL. Of 798 DLBCL patients, 42 (5.3%) were identified as AYA (16-39 years). The characteristics of AYA DLBCL patients showed no significant differences compared to older adult DLBCL patients (age ≥ 40 years). Progression-free survival (PFS) and overall survival (OS) in AYA were similar to those in patients aged 40-60 years. However, in older adult groups, PFS and OS were significantly different according to the age group (40-60, 61-79, and ≥ 80 years). In univariate analysis in AYA, performance status, clinical stage, International Prognostic Index (IPI), and age-adjusted IPI significantly affected both PFS and OS. In multivariate analysis, only clinical stage was identified as an independent predictor among AYA. In conclusion, disease characteristics and outcomes of DLBCL in AYA were nearly the same as those in older adults.

Entities:  

Keywords:  Adolescents; Clinical practice; Diffuse large B-cell lymphoma; Non-Hodgkin lymphoma; Young adults

Mesh:

Year:  2018        PMID: 29605873     DOI: 10.1007/s12185-018-2449-8

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  22 in total

Review 1.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors:  B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

2.  Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Authors:  Tina Marie Green; Ken H Young; Carlo Visco; Zijun Y Xu-Monette; Attilio Orazi; Ronald S Go; Ole Nielsen; Ole V Gadeberg; Torben Mourits-Andersen; Mikael Frederiksen; Lars Møller Pedersen; Michael Boe Møller
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

3.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Authors:  Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

4.  Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial.

Authors:  Ilske Oschlies; Wolfram Klapper; Martin Zimmermann; Matthias Krams; Hans-Heinrich Wacker; Birgit Burkhardt; Lana Harder; Reiner Siebert; Alfred Reiter; Reza Parwaresch
Journal:  Blood       Date:  2006-01-19       Impact factor: 22.113

Review 5.  Lymphoma in adolescents and young adults.

Authors:  Samantha M Jaglowski; Erica Linden; Amanda M Termuhlen; Joseph M Flynn
Journal:  Semin Oncol       Date:  2009-10       Impact factor: 4.929

6.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Authors:  Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

7.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Authors:  Nathalie A Johnson; Graham W Slack; Kerry J Savage; Joseph M Connors; Susana Ben-Neriah; Sanja Rogic; David W Scott; King L Tan; Christian Steidl; Laurie H Sehn; Wing C Chan; Javeed Iqbal; Paul N Meyer; Georg Lenz; George Wright; Lisa M Rimsza; Carlo Valentino; Patrick Brunhoeber; Thomas M Grogan; Rita M Braziel; James R Cook; Raymond R Tubbs; Dennis D Weisenburger; Elias Campo; Andreas Rosenwald; German Ott; Jan Delabie; Christina Holcroft; Elaine S Jaffe; Louis M Staudt; Randy D Gascoyne
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544

Review 8.  Classification of lymphoid neoplasms: the microscope as a tool for disease discovery.

Authors:  Elaine S Jaffe; Nancy Lee Harris; Harald Stein; Peter G Isaacson
Journal:  Blood       Date:  2008-12-01       Impact factor: 22.113

Review 9.  Adolescents and young adults with non-Hodgkin's lymphoma: slipping between the cracks.

Authors:  Ofir Wolach; Ron Ram
Journal:  Acta Haematol       Date:  2014-09-10       Impact factor: 2.195

10.  Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group.

Authors:  F Hayakawa; T Sakura; T Yujiri; E Kondo; K Fujimaki; O Sasaki; J Miyatake; H Handa; Y Ueda; Y Aoyama; S Takada; Y Tanaka; N Usui; S Miyawaki; S Suenobu; K Horibe; H Kiyoi; K Ohnishi; Y Miyazaki; S Ohtake; Y Kobayashi; K Matsuo; T Naoe
Journal:  Blood Cancer J       Date:  2014-10-17       Impact factor: 11.037

View more
  4 in total

1.  The better outcomes of diffuse large B-cell lymphoma in adolescents and young adults.

Authors:  Junnan Wang; Fengshang Yan; Yiran Wang
Journal:  Int J Hematol       Date:  2018-07-14       Impact factor: 2.490

2.  Efficacy and safety comparison between R-CHOP and modified NHL-BFM-90 regimens in children and adolescents with diffuse large B-cell lymphoma.

Authors:  Jinqiu Guan; Feifei Sun; Juan Wang; Zijun Zhen; Xiaofei Sun; Yizhuo Zhang; Junting Huang; Suying Lu; Jia Zhu; Xiaoqin Zhu; Huiqiang Huang; Zhongjun Xia; Yi Que; Ruiqing Cai
Journal:  Ann Hematol       Date:  2022-01-08       Impact factor: 3.673

3.  Disparities in the long-term survival of adolescent and young adult diffuse large B cell lymphoma survivors.

Authors:  Amy M Berkman; Clark R Andersen; Vidya Puthenpura; J A Livingston; Sairah Ahmed; Branko Cuglievan; Michelle A T Hildebrandt; Michael E Roth
Journal:  Cancer Epidemiol       Date:  2021-09-28       Impact factor: 2.984

4.  Retrospective analysis of adolescent and young adult with lymphoma at two cancer facilities in Japan.

Authors:  Aya Nakaya; Shinya Fujita; Atsushi Satake; Takahisa Nakanishi; Yoshiko Azuma; Yukie Tsubokura; Ryo Saito; Akiko Konishi; Masaaki Hotta; Hideaki Yoshimura; Kazuyoshi Ishii; Tomoki Ito; Shosaku Nomura
Journal:  Leuk Res Rep       Date:  2019-05-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.